To see the other types of publications on this topic, follow the link: Giovanni Alessandro.
Journal articles on the topic 'Giovanni Alessandro'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Giovanni Alessandro.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Kieven, Elisabeth. "An Italian Architect in London: The Case of Alessandro Galilei (1691–1737)." Architectural History 51 (2008): 1–31. http://dx.doi.org/10.1017/s0066622x00003002.
Full textAbstract:
‘I will carry with me the best architect in Europe.’ With these bold words Robert, first Viscount Molesworth, announced to his wife his arrival in Ireland in the company of the young Italian architect and engineer Alessandro Galilei in May 1717. Lord Molesworth could not know that, twenty years later, Galilei would be indeed one of the best-known architects in Europe, after having built in Rome, to the order of Pope Clement XII Corsini (1730–40), the facade of San Giovanni in Laterano (St John Lateran), the Cappella Corsini in the same church and the facade of San Giovanni dei Fiorentini.Galilei was born on 25 August 1691, in Florence, the eldest son of the notary Giuseppe Maria Galilei and his wife Margherita Merlini. The Galilei family could trace their lineage to the Buonaiuti, who in the fourteenth century twice held the post of ‘Gonfaloniere della Giustizia’, then the most important position in the city government. They took the surname Galilei from the last Gonfaloniere in their family, the master of philosophy and medicine, Galileo (early fifteenth century). Even into the sixteenth century, members of the family belonged to the town council. The most famous bearer of the name was without doubt Galileo Galilei (1564–1641), from whom Alessandro was not directly descended but to whom he was remotely related. Although Alessandro’s father, Giuseppe, who in 1707 and 1711 was Proconsul of Notaries, counted himself as one of the nobili, the standing of the old patrician families had been considerably reduced under the Medici Grand Dukes because they did not actually hold a landed title. Financial decline seems also to have damaged the prestige of Alessandro’s branch of the family.
2
Zapperi, Roberto. "Alessandro Farnese, Giovanni della Casa and Titian's Danae in Naples." Journal of the Warburg and Courtauld Institutes 54 (1991): 159. http://dx.doi.org/10.2307/751486.
Full text
3
Peintinger, Barbara. "Giovanni Alessandro Brambillas Appendice – eine Quelle zum Gesundheitswesen im Josephinismus." VIRUS - Beiträge zur Sozialgeschichte der Medizin 1 (2020): 147–55. http://dx.doi.org/10.1553/virus10s147.
Full text
4
Farneti, Fauzia. "Il quadraturismo in Pallazzo Pitti da Cosimo II a Cosimo III de' Medici." Varia Historia 24, no. 40 (2008): 369–86. http://dx.doi.org/10.1590/s0104-87752008000200002.
Full textAbstract:
Nei primi decenni del Seicento la pittura decorativa a Firenze risulta ancora legata all'ornamentazione tradizionale tardomanierista attuata nei modi di Alessandro Allori o di Bernardino Barbatelli detto il Poccetti. L'interesse per le novità e per l'aggiornamento dell'ambiente artistico fiorentino portarono il granduca Ferdinando II a chiamare a Firenze tra il 1636 ed il 1637 Pietro da Cortona, Angelo Michele Colonna e Agostino Mitelli. I due bolognesi completarono il ciclo pittorico celebrativo del governo di Ferdinando cui aveva dato inizio Giovanni da San Giovanni, con la decorazione delle tre sale di rappresentanza del quartiere estivo di palazzo Pitti realizzata tra il 1637 ed il 1641. L'intervento, condotto secondo il più moderno linguaggio barocco che vede la perfetta integrazione dell'illusionismo architettonico, che supera i limiti dello spazio reale, con le scene figurative, verrà a costituire nell'ambiente fiorentino un ineludibile modello di riferimento nella decorazione d'interni, soluzioni di grande modernità su cui si formerà Jacopo Chiavistelli e i giovani della sua scuola. Anche Giovan Carlo, fratello del granduca, nel 1637 diede inizio ad una serie di trasformazioni che si protrassero per oltre un ventennio, trasformando gli ambienti a lui assegnati in Pitti in veri e propri luoghi di delizie, decorati dagli artisti più significativi del momento quali ad esempio Angelo Michele Colonna, Agostino Mitelli, Pietro da Cortona, Jacopo Chiavistelli. Fu quest'ultimo frescante che con i suoi 'scolari', fin dagli anni Cinquanta fu attivo in palazzo Pitti, decorando a quadratura gli ambienti dei quartieri dei membri della famiglia granducale, ambienti che in gran parte sono andati perduti in quanto interessati dalle ristrutturazioni lorenesi e sabaude. Con i lavori commissionati dal gran principe Ferdinando si chiude in palazzo Pitti la grande stagione del quadraturismo barocco fiorentino.
5
Romero Benguigui, Daniel. "Caprara, Giovanni y Alessandro Ghignoli (dirs.) (2015). TENDENCIAS CULTURALES EN ITALIA. ENTRE LITERATURA, ARTE Y TRADUCCIÓN." Entreculturas. Revista de traducción y comunicación intercultural, no. 7-8 (January 1, 2016): 1009–11. http://dx.doi.org/10.24310/entreculturasertci.vi7-8.11508.
Full textAbstract:
Tendencias culturales en Italia: Entre literatura, arte y traducción, proyecto dirigido por Giovanni Caprara y Alessandro Ghignoli, ambos docentes de la Universidad de Málaga, contempla un objetivo muy claro: abarcar los elementos definitorios de la cultura italiana a través de diversas manifestaciones. Para alcanzar esta meta no se ocupa únicamente de la literatura nacional (aunque esta conforma una parte importante de la obra), sino que procura extenderse a otras facetas de la cultura, como perfectamente se indica en el subtítulo.
6
Terrone, Enrico. "Alessandro Armando e Giovanni Durbiano, Teoria del progetto architettonico. Dai disegni agli effetti." Rivista di estetica, no. 67 (April 1, 2018): 230–35. http://dx.doi.org/10.4000/estetica.2870.
Full text
7
Newcomb, Anthony. "The New Roman Style and Giovanni Maria Nanino." Journal of Musicology 36, no. 2 (2019): 167–94. http://dx.doi.org/10.1525/jm.2019.36.2.167.
Full textAbstract:
As a composer of secular music, Giovanni Maria Nanino seems to have published only three books of madrigals and one of canzonettas, yet he contributed numerous pieces to anthologies, and his madrigals were often reprinted. Scarcely an important anthology appeared in these years without a contribution by him. Indeed in the fifteen years before the death of Giovanni Pierluigi da Palestrina in 1594, Nanino rivaled him as the most esteemed of Roman composers; in the decade after Palestrina’s death, Nanino was the undisputed head of the large and important Roman school. By certain measures Nanino was the most often represented composer in anthologies printed between 1570 and 1620. In this area he surpasses not only Palestrina, but also Luca Marenzio, Philippe de Monte, and Alessandro Striggio. Despite Nanino’s immense prestige among his contemporaries, in modern histories his secular music is scarcely discussed, with just a passing mention in Alfred Einstein’s voluminous The Italian Madrigal. This article establishes Nanino’s leadership in defining the new Roman style of madrigal in the late sixteenth century, outlines its musical characteristics, and suggests paths for future research into this as yet little studied school.
8
Katorova, A. A., and Y. S. Boronenkova. "The evolution of the Italian novel (based on the works of Clorinda Di Fini), part 1." Язык и текст 4, no. 1 (2017): 17–38. http://dx.doi.org/10.17759/langt.2017040103.
Full textAbstract:
The article deals with the evolution of the Italian novel in different literary and historical periods, starting with the epic poem of Antiquity up to the historical novel (“The Betrothed” by Alessandro Manzoni) and the social novel (“The House by the Medlar-Tree” and “Mastro-don Gesualdo” by Giovanni Verga). Based on the works of Italian philologist Clorinda Di Fini, the article shows how the focus of narrative shifts from the fate of the upper classes to the lives of ordinary people in a larger historical context, as well as the author's position in the novel moves towards impersonality and objective reflection on social problems
9
Katorova, A. A., and Y. S. Boronenkova. "The evolution of the Italian novel (based on the works of Clorinda Di Fini), part 2." Язык и текст 4, no. 2 (2017): 14–31. http://dx.doi.org/10.17759/langt.2017040203.
Full textAbstract:
The article deals with the evolution of the Italian novel in different literary and historical periods, starting with the epic poem of Antiquity up to the historical novel (“The Betrothed” by Alessandro Manzoni) and the social novel (“The House by the Medlar-Tree” and “Mastro-don Gesualdo” by Giovanni Verga). Based on the works of Italian philologist Clorinda Di Fini, the article shows how the focus of narrative shifts from the fate of the upper classes to the lives of ordinary people in a larger historical context, as well as the author's position in the novel moves towards impersonality and objective reflection on social problems.
10
Prokop, Krzysztof R. "Sukcesja święceń biskupich pasterzy Kościoła warszawskiego (1798-2007)." Prawo Kanoniczne 53, no. 1-2 (2010): 315–66. http://dx.doi.org/10.21697/pk.2010.53.1-2.16.
Full textAbstract:
Nel presente articolo è stata trattata la problematica della successione apostolica (delle ordinazioni episcopali) dei pastori della diocesi (dal 1818 archidiocesi) di Varsavia. Prima sono presentati insieme i dati riguardanti le ordinazioni episcopali dei singoli vescovi ordinari, arcivescovi metropoliti ed ausiliari, nonché degli insigniti di dignità vescovile amministratori apostolici della Chiesa di Varsavia. Poi, questi presuli sono stati aggregati alle distinte, nella letteratura d’argomento, linee della successione delle ordinazioni episcopali. I trattati nel presente lavoro membri dell’episcopato cattolico – enumerando in ordine cronologico secondo la data dell’ordinazione episcopale – sono: Adalberto Giuseppe Skarszewski (1791), Giovanni Battista Albertrandi (1796), Giuseppe Miaskowski (1800), Francesco Malczewski (1815), Giovanni Paolo Woronicz (1816), Daniele Elia Ostrowski (1816), Stefano Hołowczyc (1819), Niccolò Giovanni Manugiewicz (1822), Francesco Pawłowski (1827), Stanislao Choromański (1829), Tomasso Chmielewski (1837), Antonio Melchiore Fijałkowski (1842), Giovanni Dekert (1859), Enrico Lodovico Plater (1859), santo Sigismondo Feliński (1862), Vincenzo Teofilo Popiel (1863), Casimiro Ruszkiewicz (1884), Alessandro Kakowski (1913), Stanislao Gall (1918), Ladislao Szcześniak (1925), Augusto Hlond (1926), Antonio Ladislao Szlagowski (1928), Stefano Wyszyński (1946), Sigismondo Choromański (1946), Venceslao Majewski (1946), Giorgio Modzelewski (1959), Bronislao Dąbrowski (1962), Ladislao Miziołek (1969), Sbigneo Giuseppe Kraszewski (1970), Giuseppe Glemp (1979), Casimiro Romaniuk (1982), Mariano Duś (1986), Stanislao Kędziora (1987), Casimiro Nycz (1988), Giuseppe Zawitkowski (1990), Slavoj L. Głódź (1991), Pietro Jarecki (1994), Stanislao Wielgus (1999) e Taddeo Pikus (1999). Tra essi la maggioranza apparteneva alla linea polacca (famiglia di Lorenzo Gembicki/Claudio Rangoni) e solo tre – G.B. Albertrandi, G. Miaskowski, C. Nycz – rappresentano la linea romana (famiglia di Scipione Rebiba).
11
Parent, André. "Giovanni Aldini: From Animal Electricity to Human Brain Stimulation." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 31, no. 4 (2004): 576–84. http://dx.doi.org/10.1017/s0317167100003851.
Full textAbstract:
Two hundred years ago, Giovanni Aldini published a highly influential book that reported experiments in which the principles of Luigi Galvani (animal electricity) and Alessandro Volta (bimetallic electricity) were used together for the first time. Aldini was born in Bologna in 1762 and graduated in physics at the University of his native town in 1782. As nephew and assistant of Galvani, he actively participated in a series of crucial experiments with frog's muscles that led to the idea that electricity was the long-sought vital force coursing from brain to muscles. Aldini became professor of experimental physics at the University of Bologna in 1798. He traveled extensively throughout Europe, spending much time defending the concept of his discreet uncle against the incessant attacks of Volta, who did not believe in animal electricity. Aldini used Volta's bimetallic pile to apply electric current to dismembered bodies of animals and humans; these spectacular galvanic reanimation experiments made a strong and enduring impression on his contemporaries. Aldini also treated patients with personality disorders and reported complete rehabilitation following transcranial administration of electric current. Aldini's work laid the ground for the development of various forms of electrotherapy that were heavily used later in the 19th century. Even today, deep brain stimulation, a procedure currently employed to relieve patients with motor or behavioral disorders, owes much to Aldini and galvanism. In recognition of his merits, Aldini was made a knight of the Iron Crown and a councillor of state at Milan, where he died in 1834.
12
Gili, Luca. "Il confronto di Giovanni Filopono con Alessandro di Afrodisia intorno al problema della conversione delle proposizioni." Elenchos 36, no. 2 (2015): 317–40. http://dx.doi.org/10.1515/elen-2015-360206.
Full textAbstract:
AbstractIn this paper I compare Philoponus’s account of the laws of conversion for categorical and modal propositions with Alexander’s exposition of the same topic. I argue that Philoponus’s main source was Alexander’s commentary on Aristotle’s Prior Analytics and that Philoponus had no access to independent sources to reconstruct Theophrastus’s proof for the conversion of universal negative propositions. I suggest that the different solutions that Alexander and Philoponus offer to the puzzles of the doctrine of the laws of conversion depend on the two commentators’ different exegetical strategies. Alexander tries to solve the puzzles by means of doctrines, which Aristotle expounded elsewhere. Philoponus instead interprets Aristotle’s passage as implying a hierarchy among propositions - a doctrine which is not explicitly present in Aristotle’s text.
13
Thaler, Kai M. "Political Leadership in Africa: Leaders and Development South of the Sahara by Giovanni Carbone and Alessandro Pellegata." Journal of Interdisciplinary History 52, no. 2 (2021): 296–98. http://dx.doi.org/10.1162/jinh_r_01721.
Full text
14
Mazzacane, Aldo. "Alessandro Dani, Un'immagine secentesca del diritto comune. La teoria delle fonti nel pensiero di Giovanni Battista De Luca." Zeitschrift der Savigny-Stiftung für Rechtsgeschichte: Romanistische Abteilung 128, no. 1 (2011): 701–5. http://dx.doi.org/10.7767/zrgra.2011.128.1.701.
Full text
15
&NA;. "Both images from, Giovanni Alessandro Brambilla's Instrumentarium chirurgicum Viennense; oder, Wiennerische chirurgische Instrumenten Sammlung. Wien, Matthias Andreas Schmidt, 1781." Neurosurgery 48, no. 6 (2001): 1407. http://dx.doi.org/10.1097/00006123-200106000-00057.
Full text
16
&NA;. "Both images from, Giovanni Alessandro Brambilla's Instrumentarium chirurgicum Viennense; oder, Wiennerische chirurgische Instrumenten Sammlung. Wien, Matthias Andreas Schmidt, 1781." Neurosurgery 48, no. 6 (2001): 1407. http://dx.doi.org/10.1227/00006123-200106000-00057.
Full text
17
Bellew, R. Shelton. "Examining the apocalyptic in Roberto Saviano’s Gomorra." Forum Italicum: A Journal of Italian Studies 52, no. 2 (2018): 505–22. http://dx.doi.org/10.1177/0014585818755358.
Full textAbstract:
This article examines the apocalyptic in Gomorra ( Saviano, 2006 ). Wu Ming 1 (2008) declared Saviano’s novel to be part of a new body of literature called the “New Italian Epic” based upon the narrative’s seven characteristics. Alessandro Dal Lago (2010) , on the other hand, does not think that Saviano’s work represents a new genre. For him, Ming’s sixth characteristic, the unidentified narrative object, has been the narrative technique of various historical authors such as Giovanni Verga (1978) and almost any work by Jorge Borges, just to name two. This technique is that of a composite narrator, which employs mimesis in combination with a diegetic narrative that alternates between being intradiegetic and extradiegetic according to the author’s whim. In assessing Gomorra, Dal Lago argues that there has always been literature that appears to tell an objective truth but that, in fact, represents the author’s subjective portrayal. He calls this writing style the “heroic rhetoric.” Dal Lago is correct in assessing this rhetorical style, but does not fully explain Saviano’s popular success. This article will review the apocalyptic literature to show how it applies to the narrative of Saviano’s prophetic voice in an eschatological context.
18
Carter, Tim. "Cerberus Barks in Vain: Poetic Asides in the Artusi–Monteverdi Controversy." Journal of Musicology 29, no. 4 (2012): 461–76. http://dx.doi.org/10.1525/jm.2012.29.4.461.
Full textAbstract:
The numerous documents associated with the controversy launched in 1600 by the Bolognese music theorist Giovanni Maria Artusi (1546–1613) against the madrigals of Claudio Monteverdi (1567–1643) have been well studied by scholars. But no one has yet engaged with the encomia included in the front and back matter of the printed books lying at the heart of the dispute: three sonnets (two by Vicenzo Maria Sandri and one by Mutio Manfredi) and a Latin carmen (by Erycius Puteanus) in the treatise L’Artusi, overo Delle imperfettioni della moderna musica (1600), and two madrigals by the poet and theologian Cherubino Ferrari in Monteverdi’s Il quinto libro de madrigali a cinque voci (1605). Although one might dismiss them as mere “occasional” poetry flattering Artusi, on the one hand, and Monteverdi, on the other, as well as their respective patrons, close reading suggests that these encomia represent attempts to claim the high ground not just on musical but also on philosophical and even religious terms. Ferrari’s praise of the composer finds a clear echo in Alessandro Striggio the Younger’s libretto for Monteverdi’s opera Orfeo (1607). All this provides an intriguing footnote, and perhaps something more, both to the controversy over the seconda pratica madrigal and to Orfeo in their broader Ferrarese and Mantuan contexts.
19
CAMEROTA, FILIPPO. "IL DISEGNO DEL TERRITORIO E LA DIFESA DELLO STATO." Nuncius 14, no. 2 (1999): 455–69. http://dx.doi.org/10.1163/182539199x00030.
Full textAbstract:
Abstracttitle SUMMARY /title The National Archive of Lucca holds an extensive collection of drawings that document a wide-ranging campaign of topographical surveys carried out between 1580 and 1583 for the purpose of tracing a detailed map of fortifications under the domain of the Republic of Lucca. The surveys lie chronologically between the map drawn by the military engineer Alessandro Resta in 1567 and the accurate chorography of the State of Lucca produced at the end of the same century by the Paduan cosmographer Giovanni Antonio Magini. Historical circumstances suggest that the surveys may be attributed to the military engineer Vincenzo Civitali, who had been hired during that period to superintend the State's fortifications along the border between the Duchy of Modena and the Grand Duchy of Tuscany. Apart from providing information on the Republic's cartographic and defense projects, these drawings provide firsthand documentation of the work of a 16th C. topographer, as well as revealing the strategy applied when locating measuring stations which often coincided with a signaling tower, the choice of measuring instruments most readily associated with the simple theodolite, and the adoption of a surveying methodology that consisted in measuring azimuths and distances according to the codified precepts of 16th C. treatise writers.
20
Houston, W. J. "Le sorti e le vesti: La “Scrittura” alle radici del messianismo giovanneo tra re-interpretazione e adempimento: Sal 22(21) a Qumran e in Giovanni, written by Alessandro Cavicchia." Vetus Testamentum 65, no. 4 (2015): 660–61. http://dx.doi.org/10.1163/15685330-12341240-05.
Full text
21
Spagnoletti, Angelantonio. "Le dinastie italiane e la guerra delle Fiandre." SOCIETÀ E STORIA, no. 125 (December 2009): 423–43. http://dx.doi.org/10.3280/ss2009-125002.
Full textAbstract:
- In this essay the author deals with the Italian princes and noblemen who took part in the war of the Flanders. In the second half of the eighteenth century and the first half of the nineteenth century the nationalist historiography considered them as the only men who were still able to preserve the honour of a nation ruled by the sovereigns who were subject to Spain. Emanuele Filiberto, Alessandro Farnese and Ambrogio Spinola were good examples of an invincible fighting spirit. In fact, the Italians held an important position in the multinational Spanish army; many southern princes and barons often went to the Flanders with their families. In many cases they had received the baptisim of fire under the orders of don Giovanni of Austria, during the historical period starting from the battle of Lepanto to the conquest of Tunis, The author emphasizes that the presence of many foreign princes and noblemen in the military encampments and battlefields of the Flanders forced them to follow precise and codified rules of behaviour belonging to the courtly world. Such rules couldn't be avoided. Moreover, the military experience abroad had a deep effect on their future destiny. The Kings'gratitude towards the Italians who returned from the Flanders was rewarded with public posts and honours, however it was limited due to the fact that those had been foreign battles.
22
Pinna, Giovanni. "Alessandro Minelli;, Sandra Casellato (Editors). Giovanni Canestrini: Zoologist and Darwinist. 605 pp., bibls., index. Venezia: Istituto Veneto di Scienze, Lettere, ed Arti, 2001. €56.81 (paper)." Isis 94, no. 3 (2003): 534–35. http://dx.doi.org/10.1086/380696.
Full text
23
CONFORTI, MARIA. "ALESSANDRO PASTORE e GIOVANNI ROSSI, Paolo Zacchia. Alle origini della medicina legale (1584-1659). Milano: F. Angeli, 2008. 351 pp., ISBN 978-88-56800-23-4." Nuncius 25, no. 1 (2010): 146–48. http://dx.doi.org/10.1163/221058710x00176.
Full text
24
Connors, Joseph. "Review: Le vite de' pittori, scultori, ed architetti..., Rome, 1642 by Giovanni Baglione, Jacob Hess, Herwarth Röttgen; Die Künstlerbiographien von Giovanni Battista Passeri by Jacob Hess; Vite de' pittore, scultori ed architetti moderni by Lione Pascoli, Valentino Martinelli, Alessandro Marabottini." Journal of the Society of Architectural Historians 57, no. 4 (1998): 469–71. http://dx.doi.org/10.2307/991466.
Full text
25
Murgia, Gisella. "Sardegna tra leggenda e realtà: ‘Sa femmina accabadora’, colei che dà la buona morte, nelle immagini e nelle parole di alcuni autori sardi." Italianistica Debreceniensis 24 (December 1, 2018): 77–84. http://dx.doi.org/10.34102/italdeb/2018/4662.
Full textAbstract:
The term accabadora refers to a woman entrusted with the task of facilitating the passing of the dying people. She killed for pity, called by the families of the patients to relieve their sufferings on their own deathbed. Basically, she practiced a sort of ante litteram euthanasia. But that carried out by the woman was also a necessary action for the survival of relatives who, most of the time, did not have the necessary resources to alleviate the sufferings of the kinsmen. Furthermore, in small towns, the doctor was often several days away on horseback. While the accabadora took life away, on the other hand, she gave it back, helping the women of her community to give birth. Everyone in the village knew the activity of these women but all of them were silent. They were convinced that the work of the accabadora was a meritorious work because it took the burden of putting an end to the sufferings of the patient. They implicitly recognized in it a social utility. After outlining the figure of 'sa fèmmina practica', this report analyses some works by Sardinian authors who are interested in it. Above all, we will mention the novel by Michela Murgia, Accabadora (Campiello prize 2010); the film by Enrico Pau, L'accabadora; the novels L’ultima agabbadòra by Sebastiano Depperu and L'agabbadora. La morte invocata by Giovanni Murineddu; the short film Deu ci sia by Gianluca Tarditi, winner of the 2011 Golden Globe at 48th New York Film Festival; Ho visto agire s’accabadora by Dolores Turchi; Eutanasia ante litteram in Sardegna. Sa femmina accabadora by Alessandro Bucarelli and Carlo Lubrano and S’accabadora e la sacralità del femminino of Maria Antonella Arras.
26
Izbicki, Thomas M. "All’indomani del grande Scisma d’Occidente. Jean Le Fèvre canonista al servizio dei Valois e il trattato De planctu bonorum in risposta a Giovanni da Legnano by Alessandro Fabbri." Catholic Historical Review 100, no. 3 (2014): 599–600. http://dx.doi.org/10.1353/cat.2014.0174.
Full text
27
Latosińska, Agnieszka. "Book Review: Luciano Canfora, Andrea Giardina, Chiara Frugoni, Alessandro Barbero, Alberto Mario Banti, Emilio Gentile, Andrea Graziosi, Vittorio Vidotto, Giovanni Sabbatucci, Andrea Riccardi, Michelle Perrot, I Volti Del Potere, Roma–Bari: Editori Late." Polish Political Science Yearbook 41, no. 1 (2012): 5–4. http://dx.doi.org/10.15804/ppsy2012035.
Full text
28
Monti, S., L. Dagna, C. Campochiaro, et al. "FRI0212 THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 689.1–690. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3779.
Full textAbstract:
Background:Giant cell arteritis (GCA) is the most frequent systemic vasculitis after the age of 50 years old. Recent interest in the processes of immune and vascular aging have been proposed as a disease risk factor. Data on the impact of age at diagnosis of GCA on the clinical course of the disease are scarceObjectives:To assess the role of age at diagnosis of GCA on the risk and time to relapseMethods:Centres participating in the Italian Society of Rheumatology Vasculitis Study Group retrospectively enrolled patients with a diagnosis of GCA until December 2019. The cohort was divided in tertiles according to age at diagnosis (≤ 72; 73-79; > 79 years old). Negative binomial regression was used to assess the relapse rate according to age groups, and Cox regression for time to first relapse.Results:Of 720 patients enrolled in 14 Italian reference centres, 711 had complete follow-up data (female 50%; mean age 75±7). Median follow-up duration was 34 months (IQR 16;70). Patients in the older group at diagnosis (> 79 years) had more frequent visual loss compared to the 73-79 and ≤ 72 age groups (31% vs 20% vs 7%; p<0.001), but lower rates of general symptoms (56% vs 70% vs 77%; p<0.001). Large-vessel (LV)-GCA was less frequent in the older group (18% vs 22% vs 43%; p<0.001). At least one relapse occurred in 47% of patients. Median time to relapse was 12 months (IQR 6;23). Age did not influence the rate of relapses [18 per 100 persons/years (95%CI 15;21) vs 19 (95% CI 17;22) vs 19 (95%CI 17;22)], nor the time to first relapse (Figure 1). LV-GCA, presentation with significantly elevated c-reactive protein (> 50 mg/L) and general symptoms were independent predictors of relapse.Conclusion:Age at diagnosis of GCA influenced the clinical presentation and risk of ischaemic complications, but did not affect the relapse rate during follow-up. LV-GCA occurred more frequently in younger patients and was an independent predictor of relapse risk, highlighting the need for a correct characterization of the clinical subtype at the early stages of disease.Disclosure of Interests:Sara Monti: None declared, Lorenzo Dagna Grant/research support from: Abbvie, BMS, Celgene, Janssen, MSD, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, SG, SOBI, Consultant of: Abbvie, Amgen, Biogen, BMS, Celltrion, Novartis, Pfizer, Roche, SG, and SOBI, Corrado Campochiaro Speakers bureau: Novartis, Pfizer, Roche, GSK, SOBI, Alessandro Tomelleri: None declared, Giovanni Zanframundo: None declared, Catherine Klersy: None declared, Francesco Muratore: None declared, Luigi Boiardi: None declared, Roberto Padoan: None declared, Mara Felicetti: None declared, Franco Schiavon: None declared, Milena Bond: None declared, Alvise Berti: None declared, Roberto Bortolotti: None declared, Carlotta Nannini: None declared, Fabrizio Cantini: None declared, Alessandro Giollo: None declared, Edoardo Conticini: None declared, angelica gattamelata: None declared, Roberta Priori: None declared, Luca Quartuccio Consultant of: Abbvie, Bristol, Speakers bureau: Abbvie, Pfizer, Elena Treppo: None declared, Giacomo Emmi: None declared, Martina Finocchi: None declared, Giulia Cassone: None declared, Ariela Hoxha Speakers bureau: Celgene, UCB, Novartis, Sanofi, Werfen, Rosario Foti Consultant of: lilly, sanofi, MSD, Janssen, Abbvie, BMS, celgene, roche, Speakers bureau: lilly, sanofi, MSD, Janssen, Abbvie, BMS, celgene, roche, Michele Colaci: None declared, Roberto Caporali Consultant of: AbbVie; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme; Celgene; Bristol-Myers Squibb; Pfizer; UCB, Speakers bureau: Abbvie; Bristol-Myers Squibb; Celgene; Lilly; Gilead Sciences, Inc; MSD; Pfizer; Roche; UCB, Carlo Salvarani: None declared, Carlomaurizio Montecucco: None declared
29
Donderer, Michael. "Federico Guidobaldi, Monica Grandi, Maria Stella Pisapia, Roberta Balzanetti, Annali-sa Bigliati: Mosaici antichi in Italia. Regione prima. Ercolano. Presentazione di Pietro Giovanni Guzzo. Premessa di Maria Paola Guidobaldi. Con la collaborazione di Alessandra D’Amico (per la grafica) e Alessandro Lugari (per gli aspetti conservativi). 2 vol." Gnomon 90, no. 5 (2018): 458–63. http://dx.doi.org/10.17104/0017-1417-2018-5-458.
Full text
30
Ramos, Flamarion Caldeira. ""Il giovane Schopenhauer. L’origine della metafisica della volontà", de Alessandro Novembre." Voluntas: Revista Internacional de Filosofia 10, no. 2 (2019): 162. http://dx.doi.org/10.5902/2179378639615.
Full text
31
Kohl, Benjamin G. "Roberto Cardini, Eugenio Garin, Lucia Cesarini Martinelli, and Giovanni Pascucci, eds. Tradizione classica e letteratura umanistica: per Alessandro Perosa. (Humanistica, 3-4.) Rome: Bulzoni Editore, 1985. 2 vols.: 23 plates + xxvi + 814 pp. L.90,000." Renaissance Quarterly 40, no. 3 (1987): 514–16. http://dx.doi.org/10.2307/2862523.
Full text
32
Fassio, A., G. Adami, O. Viapiana, et al. "AB0893 THE EFFECTS OF THREE DIFFERENT VITAMIN D3 SUPPLEMENTATION REGIMENS IN DEFICIENT SUBJECTS - A RANDOMIZED OPEN-LABEL PARALLEL GROUP STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1750.2–1751. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3641.
Full textAbstract:
Background:Currently, most experts agree that levels of serum 25OH-Vitamin D (25OHD) lower than 20 ng/mL represent an acceptable threshold for deficiency (1). However, recommendations for vitamin D supplementation vary between scientific societies, and the best regimen to treat deficient patients is still not clear (1).Objectives:The aim of our study was to compare the pharmacokinetic profile of three different regimes of cholecalciferol supplementation in terms of 25OHD exposure and their safety profiles.Methods:We evaluated, in healthy subjects affected by vitamin D deficiency (defined as 25OHD<20 ng/mL), 18 to 60 years of age, the efficacy of three different oral supplementation regimens: daily 10,000Iu administered for 8 weeks, weekly 50,000Iu for 12 weeks and biweekly 100,000Iu for 12 weeks. Serum 25OHD was dosed at baseline, at week 2, 4, 8 in all three groups and also at week 12 in the 50,000 and 100,000Iu groups (the blood sample was taken before the drug administration if scheduled on the same day). Baseline characteristics and 25OHD changes from baseline to the various observation points were tested with ANOVA and t-test. 25OHD was measured by the IDS-ISYSMulti-Discipline automated analyser (Immunodiagnostic System, Boldon, UK) based on chemiluminescence technology. The CV intra-assay measured in our laboratory was 6% (inter-assay CV 9%). The study was authorized by the local ethical committee (protocol DIBA/11. Supported by Abiogen Pharma, Italy).Results:A total of 75 subjects were randomized to receive one supplementation regimen. The descriptive of the sample at baseline and relative 25OHD levels at the various observation points are reported in table 1. 25OHD increased significantly already at week 2 in all three groups (p=0.000). At week 2, 100% of the subject of the daily regimen group presented 25OHD levels >20ng/mL, 96% in the weekly and 88% in the biweekly ones.Table 1.mean values ± SD at the different observation points.ParameterDaily 10.000 Ui(N = 25)Weekly 50.000 Ui(n = 25)Biweekly 100.000 Ui(N = 25)p-valueM:F12:137:1812:13Age (years)30.2 ± 9.936.7 ± 8.735.4 ± 11.0*0.059Body Weight (kg)65.8 ± 13.267.8 ± 10.866.6 ± 13.7*NSHeight (m)1.7 ± 0.11.68 ± 0.11.7 ± 0.1*NSBMI22.55 ± 2.723.8 ± 2.222.8 ± 2.7*NSBaseline 25OHD (ng/mL)14.6 ± 3.912.8 ± 313.5 ± 4.1*NS25OHD week 232.3 ± 526.5 ± 3.425.6 ± 5a0.007b0.00025OHD week 455 ± 10.139.9 ± 4.236.9 ± 7.2a0.000b0.00025OHD week 879.1 ± 16.253.5 ± 7.246.4 ± 8.2a0.000b0.000c0.00125OHD week 12NA58.5 ± 7.850.6 ± 9.6b0.000c0.001*ANOVA test.aDaily 10.000 Ui vs weekly 50.000 Ui.bDaily 10.000 Ui vs Biweekly 100.000 Ui.cWeekly 50.000 Ui vs biweekly 100.000 Ui.In addition, the 25OH levels of the daily regimen group at week 8 were higher than both the ones of the weekly and the biweekly regimen groups both at week 8 and week 12 (p<0.000 vs both groups).No serious adverse event occurred.Conclusion:All the three different regimens proved to be effective in correcting vitamin D deficiency already after 1 months (2 weeks for the daily regimen). A more refracted approach seems to more effective than the bolus-based regimens. The safety profile was excellent in all groups.References:[1]R. Bouillon, Comparative analysis of nutritional guidelines for vitamin D, Nat. Rev. Endocrinol. 13 (2017) 466–479.https://doi.org/10.1038/nrendo.2017.31.Disclosure of Interests:Angelo Fassio Speakers bureau: Angelo Fassio reports personal fees from: Abiogen and Novartis, outside the submitted work., Giovanni Adami: None declared, Ombretta Viapiana: None declared, Giovanni Orsolini: None declared, Alessandro Giollo: None declared, Maurizio Rossini Speakers bureau: AbbVie, Abiogen, Amgen, BMS, Eli-Lilly, Novartis, Pfizer, Sanofi, Sandoz and UCB, Davide Gatti Speakers bureau: Davide Gatti reports personal fees from Abiogen, Amgen, Janssen-Cilag, Mundipharma, outside the submitted work.
33
Waldman, Louis A. "TWO VENETIAN PAINTERS IN DUKE ALESSANDRO'S FLORENCE: BATTISTA DI FRANCESCO DI GIOVANNI AND PAOLO DI GIOVAN GHEZZO." Source: Notes in the History of Art 28, no. 3 (2009): 19–23. http://dx.doi.org/10.1086/sou.28.3.23208537.
Full text
34
Cavagnaro, Elena. "Giovanni Reale – Abraham P. Bos, Il trattato Sul cosmo per Alessandro attribuito ad Aristotele: Monografia introduttiva, testo greco con traduzione a fronte, commentario, bibliografia ragionata e indici, Vita e Pensiero, Milano 1995, 534pp. Lit. 55.000. ISBN 88-343-0821-2." Philosophia Reformata 61, no. 2 (1996): 206–10. http://dx.doi.org/10.1163/22116117-90000119.
Full text
35
Alongi, A., A. Consolaro, G. Vijatov-Djuric, et al. "THU0498 PATIENT-REPORTED TREATMENT BURDEN AND ITS IMPACT ON QUALITY OF LIFE IN JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE PHARMACHILD REGISTRY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 486–87. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5816.
Full textAbstract:
Background:Juvenile Idiopathic Arthritis (JIA) patients experience impaired health and wellbeing due to multiple causes of physical and psychosocial distress, including treatment burden. Despite emerging evidence of its relevance [1], the contribution of treatment adverse events to patient-reported outcomes (PROs) in JIA has been poorly explored.Objectives:To evaluate and rank the impact of patient-reported adverse events (AEs) on overall wellbeing, health-related quality of life (HRQoL), school problems and self-reported medication adherence using data from Pharmachild, a large international JIA pharmacovigilance registry.Methods:Registry entries on 5340 prospective visits of 2251 patients enrolled till December 2018 were analyzed; all included patients were treated with at least one DMARDS or Biologic agent at the time of visit. In the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), patients and parents compiled a checklist of treatments, side effects, self-reported adherence, administration difficulties and disease-related school problems occurred in the previous 4 weeks. Evaluated outcomes included patient acceptable symptom state (PASS), VAS-measured patient assessment of overall wellbeing (PGA) and HRQoL, assessed through the physical health (PhH) and psychosocial health (PsH) subscales. The relationships between AEs and PROs were tested through generalized linear models, accounting for disease activity and symptoms levels. Bayesian Networks were used to explore the causal effects of specific AEs on outcomes to disentangle the confounding role of disease status.Results:AEs were reported in 22.9% of visits. For similar levels of physician global assessment (MD global), patient-assessed disease activity, pain and function, patients reporting AEs had worse PGA, PsH, and lower probability of reaching PASS (fig. 1, all p-values <0.001). The impact of AEs on PGA was small but not trivial (effect size η20.031) and appears to be mediated by effects on PsH and school problems (p <0.001). Non-linear regression modelling revealed a significant moderating effect of MD global levels < 2.5 on the relationship between AEs and PGA (p 0.003), indicating that the impact of AEs is higher for lower disease activity states. AEs predicted self-reported medication adherence (p<0.001), even when adjusted for the number of administered treatments. In the Bayesian network model, mood swing and sleep problems emerged as the most influential items affecting PsH, (respectively, total effect 2.62 and 1.25, both p< 0.001). Fig. 2 shows the total standardized effect of specific AEs on mean PsH levels. Nausea had the highest impact on treatment adherence (total effect -0.0541, p <0.001), being the only AE directly linked to drug refusal.Conclusion:AEs have a measurable effect on the wellbeing and psychosocial health of JIA patients, particularly when disease activity is low, and significantly affect school activity and medication adherence. Mood swings and sleep problems show the strongest influence on HRQoL. Addressing AEs appears important to reduce disease impact, improve patients’ satisfaction and therapeutic compliance.References: :[1]Weitzman, Elissa R., et al. Journal of patient-reported outcomes 2.1 (2018): 1.Acknowledgments:for the Paediatric Rheumatology International Trials Organisation (PRINTO)Disclosure of Interests: :Alessandra Alongi: None declared, Alessandro Consolaro Grant/research support from: Pfizer Inc., AlfaSigma, Speakers bureau: AbbVie, Gordana Vijatov-Djuric: None declared, Giovanni Filocamo: None declared, Olga Vougiouka: None declared, Alma Nunzia Olivieri: None declared, Cristina Herrera Mora: None declared, Wolfgang Emminger: None declared, Angelo Ravelli: None declared, Nicolino Ruperto Grant/research support from: Bristol-Myers Squibb, Eli Lily, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sobi (paid to institution), Consultant of: Ablynx, AbbVie, AstraZeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lily, EMD Serono, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, Sanofi, Servier, Sinergie, Sobi, Takeda, Speakers bureau: Ablynx, AbbVie, AstraZeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lily, EMD Serono, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, Sanofi, Servier, Sinergie, Sobi, Takeda
36
Blanch, Juan M. Lope. "Las Osservationi de Giovanni Miranda." Historiographia Linguistica 24, no. 1-2 (1997): 29–40. http://dx.doi.org/10.1075/hl.24.1-2.04bla.
Full textAbstract:
Summary Giovanni Miranda’s Osservationi della Lingua Castigliana (Venice, 1566) was the best pedagogical grammar of Spanish of its time; and since it served as a model to French, English, and German grammarians it was important well beyond Italy. Because it was essentially a practical teaching work, one finds in it few theoretical pronouncements. Theory, however, is not totally absent from his book, as becomes obvious in the discussion of the concept of ‘sentence’ or of the ‘parts of speech’, but as a whole the work deals with questions that were thought to be essential to the learner of a language, mostly morphology and certain peculiarities of Castilian grammar and usage. The work is divided into four parts: I, the article, the noun, the adjective, and the pronoun; II, the verb, whose conjugation is dealt with exhaustively; III, the non-inflectional parts of speech in Spanish; and IV, spelling and pronunciation. Throughout the work the author discusses related semantic, lexical, and phraseological subjects, and uses proverbs, anecdotes, and very short stories to illustrate colloquial usage of Spanish. Miranda’s Osservationi were influenced by Giovanni Mario Alessandri d’Urbino’s Paragone della Lingua Toscana et Castigliana (Naples, 1560). Miranda the format of the Paragone, but greatiy expands on it. The Osservationi della Lingua Castigliana can be said to be the first effective pedagogical grammar of Spanish written for speakers of other languages.
37
Bartolozzi, Luca, and Saverio Rocchi. "In memoria di Piero Abbazzi." Memorie della Società Entomologica Italiana 98, no. 1 (2021): 93–96. http://dx.doi.org/10.4081/memoriesei.2021.93.
Full textAbstract:
Piero Abbazzi nasce a Firenze il 21 febbraio1928. Effettua studi classici preso l’Istituto degli Scolopie si laurea in Farmacia presso l’Università degliStudi di Firenze il 21 novembre 1957. Trova presto impiegonella propaganda medica per l’industria farmaceuticaRichter, impiego che manterrà fino alpensionamento. Il 2 agosto 1959 convola a nozze conMaria Scarselli e la coppia avrà tre figli: Alessandra,Giovanni e Laura. Piero Abbazzi si spegne a 92 anni l’8marzo 2020 in ospedale a Firenze, dove era stato ricoveratoper l’aggravarsi delle sue precarie condizioni disalute, circondato dall’affetto della sua famiglia[...]
38
Nutton, Vivian. "L'esperienza del passato: Alessandro Benedetti, filologo e medico umanista. Giovanna Ferrari." Isis 89, no. 1 (1998): 127–28. http://dx.doi.org/10.1086/383944.
Full text
39
Riccardi, A., A. Marcoccia, S. Fasano, et al. "SAT0340 A REDUCED NUMBER OF CAPILLARIES AND AN INCREASED NUMBER OF MEGACAPILLARIES PREDICT THE DEVELOPMENT OF SYSTEMIC SCLEROSIS IN RAYNAUD’S PHENOMENON PATIENTS AT RISK." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1115.1–1116. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3152.
Full textAbstract:
Background:Undifferentiated connective tissue disease at risk for systemic sclerosis (UCTD-risk-SSc) is a condition characterised by Raynaud’s phenomenon and either SSc marker autoantibodies or typical capillaroscopic findings or both, unsatisfying classification criteria for SSc and evolving into definite SSc in about 30-50% of cases (1,2). Recently, we developed a weighted score based on a baseline IF-ANA titer ≥1:320, marker autoantibody positivity and presence of avascular areas at videocapillaroscopy identifying patients who will evolve with a 91.3% sensitivity and a 73.2% specificity (3).Objectives:To improve the predictivity of the score assessing the role of marker autoantibody ELISA titer and further capillaroscopic items.Methods:The 102 UCTD-risk-SSc patients investigated for the development of the previous score were reassessed for anti-Scl-70 and anti-centromere antibody titers detected by ELISA and for the mean number of capillaries observed in the same capillaroscopic field (Cs) and the total number of giant capillaries (GC) by videocapillaroscopy (4). Each patient was evaluated every 6 months to assess disease progression. Risk prediction was assessed by Cox regression analyses. The predictive value of the score was determined by receiver operating curve (ROC) analysis.Results:Table 1 shows the resulting predictive variables in multivariate Cox analysis and their relative weight in a 10-point scale. No increase in the predictivity was detected by adding the anti-Scl-70 and anti-centromere antibody ELISA titers. However, a mean number of Cs≤5/mm and GC>5 improved the score. At ROC analysis (Figure 1) a score >3.25 predicted evolution to SSc with a sensitivity of 93.5% and a 75% specificity (AUC=0.91).Table 1.Indipendent predictive variables in multivariate regression analysis and the resulting weighted prediction model *VariableβHR95% CIPWeightAnti-Scl70Cs≤5/mm2.95531.909319.216.754.87-75.762.07-22.00<0.0010.0013.252ANA ≥ 1:3201.74025.701.42-22.850.012ACA1.67405.331.51-1.900.011.75GC>51.00492.731.44-5.170.0021*β: regression coefficients; HR: hazard ratio; 95% CI: 95% confidence interval; Cs: Capillaries; ANA: anti-nuclear antibodies; ACA: anti-centromere antibodies; GC: giant capillariesConclusion:Assessing the mean number of capillaries/mm and the total number of giant capillaries instead of avascular areas at videocapillaroscopy, resulted in improving the sensitivity and specificity of the score recently developed to predict the evolution of UCTD-risk-SSc into definite SSc.References:[1]Valentini G. Autoimmun Rev 2015;[2]Valentini G. et al. Arthritis Care Res (Hoboken). 2014;[3]Riccardi A. et al. Autoimmun Rev. 2019;[4]Sambataro et al. Arthritis Research & Therapy 2014, 16:462.Disclosure of Interests:Antonella Riccardi: None declared, Antonella Marcoccia: None declared, SERENA FASANO: None declared, Tiziana Guastafierro: None declared, Rosaria Irace: None declared, Valentina Messiniti: None declared, Francesco Bondanini: None declared, Alessandro Sanduzzi: None declared, Marialuisa Bocchino: None declared, Aldo Ciani: None declared, Michele D’Alto: None declared, Paola Argiento: None declared, Giovanni Maria De Matteis: None declared, Alberto Spanò: None declared, Gabriele Valentini Grant/research support from: BMS, MSD, NOVARTIS, LILLY, PFIZER, ABBVIE, CELGENE
40
Degórski, Bazyli. "Biskupi Rzymu w "Pratum spirituale" Jana Moschosa." Vox Patrum 46 (July 15, 2004): 371–89. http://dx.doi.org/10.31743/vp.6838.
Full textAbstract:
Giovanni Mosco, nel "Pratum spirituale", menziona direttamente i tre vescovi di Roma: san Pietro Apostolo, san Leone Magno e san Gregorio Magno. San Pietro, peró, viene menzionato soltanto occasionalmente e mai direttamente. Nel presente articolo, perció, egli non viene trattato separatamente, ma solo quando e menzionato nei capitoli che presentano san Leone Magno o san Gregorio Magno. Conformemente alla nomenclatura che si e sviluppata nel primo periodo patristico, la parola „papa" non era riservata soltanto al vescovo di Roma, ma veniva utilizzata anche da altri vescovi, ad esempio: da que!li di Alessandria.
41
de Caprariis, Francesca. "NOLLI & CO.: LA SCALA DELLA PIANTA MARMOREA SEVERIANA." Papers of the British School at Rome 86 (October 26, 2017): 207–33. http://dx.doi.org/10.1017/s0068246217000368.
Full textAbstract:
L'articolo analizza i manoscritti di Diego de Revillas conservati nella Biblioteca della British School at Rome relativi alla pianta marmorea severiana e alla sua sistemazione nei Musei Capitolini nel 1742.Essi forniscono ulteriori dati su questo assai discusso lavoro, intrapreso da Giovan Battista Nolli sotto la supervisione di Alessandro Gregorio Capponi e Revillas. In particolare i documenti di Revillas gettano nuova luce sul modo in cui è stata risolta (in modo non corretto) la riduzione in scala della Forma Urbis.
42
Adami, G., A. Fassio, A. Giollo, et al. "SAT0456 REAL-LIFE RISK OF FRACTURE AND TREATMENT PREVALENCE IN DRUG-INDUCED OSTEOPOROSIS IN ITALY USING A NEW ALGORITHM." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1185.1–1186. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2565.
Full textAbstract:
Background:Glucocorticoid-induced osteoporosis and osteoporosis induced by adjuvant hormone therapy for breast cancer are the most common forms of secondary osteoporosis.Objectives:The exact real-life prevalence of treatment with anti-osteoporotic drugs in women with drug-induced osteoporosis is not known. In the present study, using a new mathematical and computerized algorithm, we investigate the profile of risk of fracture of women with drug-induced osteoporosis and the prevalence of treatment with anti-osteoporotic drugs.Methods:We have retrospectively analyzed the 10-year risk of major osteoporotic fracture calculated with the DeFRAcalc79 tool in postmenopausal women aged over 50 years that were initiating an anti-osteoporotic treatment (fully reimbursed according to the Nota 79). DeFRAcalc79 is a new web-based fracture risk-assessment tool (https://defra-osteoporosi.it) that arithmetically adjusts the risk based on multiple risk factors contemplated by the Nota 79, which regulates the reimbursability for osteoporosis medications in Italy (Italian Agency for Drugs, AIFA), including demographic and anthropometric data, femoral and/or lumbar spine BMD T-score, family history of femoral or vertebral fractures, number and site of previous osteoporotic fracture (including vertebral, femoral, and non-vertebral non-femoral fractures), glucocorticoid treatment (> 3 or > 12 months, ≥5 mg prednisone or equivalent), adjuvant hormone therapy for breast cancer, and comorbidities that induce an increased risk of fracture (rheumatoid arthritis and other connective tissue diseases, chronic obstructive pulmonary disease, inflammatory bowel diseases, Parkinson’s disease, multiple sclerosis, human immunodeficiency virus infection, diabetes, or severe physical handicap). This is a sub-analysis of the cross-sectional observational study to validate and further develop the DeFRA algorithm for the estimation of the risk of osteoporotic fractures, promoted by Verona hospital with the unconditional support of Amgen Srl.Results:Among 208 women, 116 (55.8%) were treated with adjuvant hormone therapy for breast cancer and 92 (44.2%) were on glucocorticoid ≥5 mg/day. Women on glucocorticoids had a greater mean 10-year risk of fracture compared to women on adjuvant hormone therapy for breast cancer (67.0% vs 39.1% p<0.01). 50.7% of women on adjuvant hormone therapy for breast cancer used denosumab, 28.0% zoledronic acid and 17.3% alendronate. In glucocorticoid-induced osteoporosis, 17.6% of the women used teriparatide, 37.3% alendronate, 29.4% zoledronic acid and 13.7% denosumab.Conclusion:In our cohort of patients, treatment with adjuvant hormone therapy for breast cancer was slightly more common than glucocorticoids. Women with glucocorticoid-induced osteoporosis had a greater risk of fracture compared to patients treated with adjuvant hormone therapy for breast cancer. Half of the patients on adjuvant hormone therapy for breast cancer were prescribed with denosumab. One-fifth of the patients with glucocorticoid-induced osteoporosis was treated with teriparatide. DeFRAcalc79 is a useful and practical tool for the integrated evaluation of fracture risk in drug-induced osteoporosis.Disclosure of Interests:Giovanni Adami: None declared, Angelo Fassio Speakers bureau: Angelo Fassio reports personal fees from: Abiogen and Novartis, outside the submitted work., Alessandro Giollo: None declared, Giovanni Orsolini: None declared, Ombretta Viapiana: None declared, Davide Gatti Speakers bureau: Davide Gatti reports personal fees from Abiogen, Amgen, Janssen-Cilag, Mundipharma, outside the submitted work., Maurizio Rossini Speakers bureau: AbbVie, Abiogen, Amgen, BMS, Eli-Lilly, Novartis, Pfizer, Sanofi, Sandoz and UCB
43
Losano, Mario G. "Dossier. Un progetto in Sicilia per l'inserimento dei giovani immigrati. Prologo." SOCIOLOGIA DEL DIRITTO, no. 1 (July 2012): 123–24. http://dx.doi.org/10.3280/sd2012-001006.
Full textAbstract:
La ricerca documentata in questo dossier ha per oggetto l'inserimento sociale dei giovani immigrati in Sicilia, legali o illegali. Nella ricerca (denominata "Progetto Dedalo") hanno cooperato un ente religioso di Monreale (Casa del Sorriso), una fondazione no-profit di Pavia ("Le Vele") e un gruppo di ricercatori dell'Universitŕ di Pavia. Il progetto era diretto da Mario G. Losano, Un iversitŕ del Piemonte Orientale, Alessandria, e Universidad Carlos III, Madrid. I testi qui pubblicati vennero presentati in due congressi tenutisi in Sicilia, a Monreale, nel 2009 e nel 2010.
44
Fredi, M., I. Cavazzana, A. Ceribelli, et al. "FRI0239 ANTI-NXP2 ANTIBODIES: CLINICAL AND SEROLOGICAL ASSOCIATIONS IN A MULTICENTRIC ITALIAN STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 703.1–704. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1384.
Full textAbstract:
Background:anti-NXP2 antibodies is considered a serological marker of dermatomyositis (DM), with calcinosis, severe myositis and, in some series, cancer. Historically, these associations have been detected with immunoprecipitation (IP), but in the last few years commercial lineblot (LB) assay have been released.Objectives:to analyze the clinical features associated to anti-NXP2 antibodies, including the onset of concomitant cancers, both with LB and homemade IPMethods:clinical and serological data from medical charts of 213 patients with a diagnosis of inflammatory miosidites without anti-NXP2 (NXP2-), followed-up by two third-level Centers, and 61 anti-NXP2+ patients from 10 Rheumatological centers were analyzed. Anti-myositis specific (MSA) and anti-myositis associated antibodies (MAA) were detected in single centers by LB (Euroimmun Autoimmune Inflammatory Myopathies 16 antigens). Anti-NXP2 was confirmed by protein and RNA IP, as previously described (1)Results:clinical diagnosis of anti-NXP2+ positive with LB were 42 DM, 11 PM, inclusion body myositis (IBM) 4, necrotizing myositis and overlap (OM) 1 each. Anti-NXP2+ showed a lower age at onset (p<0.0001) more frequent diagnosis of DM (68.8%vs30%,OR5.2) and IBM (6.5%vs0.49%,OR14.8), typical skin manifestations, myositis (93%vs79% OR3.3), concomitant presence of another MSA (12.7%vs2%, OR6.41) and lower rate of features associated with OM or anti-synthetase syndrome. Serum from 49 NXP2+ was available and IP analysis was made with the confirmation of NXP2 in 31 sera (63.2%) with the following diagnosis: DM 27 cases, PM 3, IBM 1. Whilst the majority of the associations were confirmed comparing NXP2LB+/IP+ with the IIM NXP2-, some peculiar associations were found significant only for the double positive patients: dysphagia (53%vs 30%,OR 2.56) and calcinosis (22%vs6.5% OR4) whereas IBM diagnosis and the presence of concomitant MSA antibodies were lost. Survival time from cancer onset is shown in figure.IP did not confirmed anti-NXP2 antibodies in 18 sera: in 4 cases at least one MSA/MAA was identified by IP; these 18 patients did not show differences when compared with 213 anti-NXP2-.Conclusion:Protein IP confirmed anti-NXP2 antibodies in 63% of LB+ sera. Double positive cases showed more typical DM features and rarely occurred in IIM not DM. Anti-NXP2 positivity by LB should be confirmed by other methods in order to correctly diagnose and characterize IIM patients.References:[1]Arthritis Res Ther 2012,30;14:R97Acknowledgments:Forum Italiano per la Ricerca Malattie Autoimmuni (FIRMA)Disclosure of Interests:Micaela Fredi: None declared, Ilaria Cavazzana: None declared, Angela Ceribelli: None declared, Maria Grazia Lazzaroni: None declared, Simone Barsotti: None declared, Maurizio Benucci: None declared, Lorenzo Cavagna: None declared, Ludovico De Stefano: None declared, Andrea Doria Consultant of: GSK, Pfizer, Abbvie, Novartis, Ely Lilly, Speakers bureau: UCB pharma, GSK, Pfizer, Janssen, Abbvie, Novartis, Ely Lilly, BMS, Giacomo Emmi: None declared, Marco Fornaro: None declared, Federica Furini: None declared, Roberto Gerli: None declared, Maria Grazia Giudizi: None declared, Marcello Govoni: None declared, Anna Ghirardello: None declared, Luca Iaccarino Speakers bureau: GSK, Pfizer, Janssen, Novartis, Florenzo Iannone Consultant of: Speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, MSD, Speakers bureau: Speaker and consulting fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, MSD, Maria Infantino: None declared, Alessandro Mathieu: None declared, Emiliano Marasco: None declared, Paola Migliorini: None declared, Boaz Palterer: None declared, paola parronchi: None declared, Matteo Piga: None declared, Federico Pratesi: None declared, Antonella Radice: None declared, Carlo Selmi: None declared, Valeria Riccieri: None declared, Marilin Tampoia: None declared, Giovanni Zanframundo: None declared, Angela Tincani: None declared, Franco Franceschini: None declared
45
De Luca, G., G. Cavalli, C. Campochiaro, et al. "CO0001 MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPER-INFLAMMATION." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 213.4–213. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6858.
Full textAbstract:
Background:Patients with severe COVID-19 pneumonia and hyperinflammation face increased mortality. There is an urgent need for effective treatments to reduce the burden of the COVID-19 pandemic.Objectives:Our protocol aimed at evaluating the potential improvement in clinical outcomes with mavrilimumab, an anti-Granulocyte/Macrophage Colony-Stimulating Factor Receptor alpha (GM-CSFRα) monoclonal antibody, in patients with COVID-19 pneumonia and systemic hyper-inflammation.Methods:Single-center, open-label, single active arm intervention; Adult patients with severe COVID-19 pneumonia (as evaluated by CT scanning), hypoxia (PaO2:FiO2 ratio ≤ 300 mmHg), and systemic hyper-inflammation (increased C-reactive protein [CRP] ≥ 100 mg/mL and/or ferritin ≥ 900 μg/L, increased lactate dehydrogenase [LDH]) received a single intravenous dose of mavrilimumab added to standard of care; follow-up 28 days. Main outcomes measure was time to clinical improvement (reduction ≥ 2 categories on the 7-point WHO clinical status scale, 1=discharge, 7=death); others included time to discharge from hospital; % of pts achieving a clinical improvement; survival; mechanical-ventilation free survival; time to fever resolution; CRP; PaO2:FiO2 ratio.Results:A mavrilimumab group (n=13 COVID-19 patients, non-mechanically ventilated, median age 57 [IQR, 52-58], males 12 [92%], febrile 11 [85%]; PaO2:FiO2195.5[166.7–215.0]) was compared to a cohort of 26 contemporaneous patients with similar baseline characteristics. Death occurred in 0% (n=0/13) of mavrilimumab recipients and 27% (n=7/26) of comparison-group patients (log rank p=0.046) during the 28-day follow-up. 100% (n=13) of mavrilimumab recipients and 65% (n=17) of comparison-group patients achieved clinical improvement (p=0.018) at Day 28, with earlier improvement (median 8.0 [IQR, 5.0–11.0] days vs 18.5 [11.0–NE] days) (p<0.001) in mavrilimumab recipients. Fever had resolved in 91% (n=10/11 febrile patients) of mavrilimumab recipients by Day 14, compared to 61% (n=11/18 febrile) of patients in the comparison group (p=0.110); fever resolution was faster in mavrilimumab recipients versus controls (median 1.0 [IQR, 1.0–2.0] day vs 7.0 [3.0 - NE] days, respectively, p=0·009). Mavrilimumab was well tolerated in all patients.Conclusion:Patients with severe COVID-19 pneumonia and systemic hyper-inflammation who received treatment with mavrilimumab had better clinical outcomes compared to patients receiving routine care. Mavrilimumab was well-tolerated. Randomized controlled trials are warranted to confirm our findings.References:[1]Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62[2]Mehta P, McAuley DF, Brown M, et al. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-4Disclosure of Interests:Giacomo De Luca Speakers bureau: SOBI, Novartis, Celgene, Pfizer, MSD, Giulio Cavalli Speakers bureau: SOBI, Novartis, Pfizer, Corrado Campochiaro Speakers bureau: Novartis, Pfizer, Roche, GSK, SOBI, Emanuel Della Torre: None declared, Piera Angelillo: None declared, Alessandro Tomelleri: None declared, nicola boffini: None declared, Stefano Tentori: None declared, Francesca Mette: None declared, Patrizia Rovere-Querini: None declared, Annalisa Ruggeri: None declared, Teresa D’Aliberti: None declared, Paolo Scarpelllini: None declared, Giovanni Landoni: None declared, Francesco De Cobelli: None declared, John F. Paolini Shareholder of: Kiniksa, Employee of: Kiniksa, Alberto Zangrillo: None declared, Moreno Tresoldi: None declared, Bruce C. Trapnell Consultant of: Kiniksa, Fabio Ciceri: None declared, Lorenzo Dagna Grant/research support from: Abbvie, BMS, Celgene, Janssen, MSD, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, SG, SOBI, Consultant of: Abbvie, Amgen, Biogen, BMS, Celltrion, Novartis, Pfizer, Roche, SG, and SOBI
46
Skibiński, Tomasz. "Ojcowie Kościoła w katechezach środowych Jana Pawła II." Vox Patrum 50 (June 15, 2007): 249–61. http://dx.doi.org/10.31743/vp.6712.
Full textAbstract:
Giovanni Paolo II durante tutto il pontificato, piu di ogni suo Predecessore, ha incontrato il Popolo di Dio. Ogni mercoledi era dedicato alle udienze generali in cui hanno partecipato 17,6 millioni di pellegrini. Generalmente durante le udienze il Papa pronunciava le catechesi, che possiamo dividere in alcuni cieli: Le quattro virtu cardinali; La redenzione del corpo e la sacramentalita del matrimonio; II Credo; La preparazione del Giubleo 2000; L’Anno Giubilare 2000; La Liturgia delle Ore. Questi cieli differenziano, tra l’altro, anche per quanto riguarda l’uso dei testi patristici. I cieli piu fondati sull’eredita patristica sono i seguenti: I commentarii ai testi della Liturgia delle Ore (pronunicate nel periodo: 28 III 2001 - 26 I 2005) e II commento al "Credo” specialmente nella parte che rigurda la fede trinitaria (catechesi pronunicate nel periodo: 3 VII1985 - 3 VII1991). Sul lato opposto si situano le Catechesi sulle virtu cardinali (pronunciate tra il 25 X e il 22 XI 1978), durante le quali i Padri della Chiesa non sono citati neanche una volta e le Catechesi sulla redenzione del corpo e la sacramentalita del matrimonio (pronunicate nel periodo: 5 IX 1979 - 28 XI 1984), in cui richiami agli autori del periodo patristico sono sporadici. Generalmente si puó constatare, che in tutto il corpo delle catechesi i richiami patristici svolgono molo importante, ed in alcuni casi sono fondamentali per la presentazione del discorso. Vengono citati Padri della Chiesa che rappresentano vari ambienti, diversi periodi e differenti scuole teologiche. I Padri preferiti da Giovanni Paolo II sono: Agostino, Ambrogio di Milano, Ireneo di Lione, Giovanni Crisostomo, Basilio di Cesarea, Cipriano, Cirillo di Gerusalemme, Cirillo di Alessandria, Ignazio di Antiochia e Origene. II Papa Wojtyła da una parte riconosce il molo che i Padri hanno svolto nella storia dell’esegesi e nella formazione del dogma, dall’altra - fa vedere la loro attualita anche nel mondo del XX e XXI secolo.
47
Adami, G., A. Fassio, A. Giollo, et al. "SAT0452 DIFFERENT PROFILE OF RISK OF FRACTURE IN PATIENTS TREATED WITH ANTI-OSTEOPOROTIC DRUGS IN ITALY USING A NEW ALGORITHM." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1183. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2559.
Full textAbstract:
Background:A new algorithm for management of patients at low, high and very high risk of osteoporotic fractures has been recently proposed, has been also recommended treating those patients at very high risk of fracture with bone anabolics (1). A similar treatment algorithm has been applied in Italy since 2015, when the “Nota 79”, that regulates the reimbursability for osteoporosis medications, has been developed by the Italian Agency for Drugs (AIFA) (2).Objectives:In the present study, using a new mathematical and computerized algorithm, we seek to investigate the profile of risk of fracture of patients starting treatment with different anti-osteoporotic medications in Italy.Methods:We retrospectively analyzed the 10-year risk of major osteoporotic fracture calculated with the DeFRAcalc79 tool in postmenopausal women aged over 50 years that were initiating an anti-osteoporotic treatment (fully reimbursed according to the Nota 79). DeFRAcalc79 is a new web-based fracture risk-assessment tool (https://defra-osteoporosi.it) that arithmetically adjusts the risk based on the integration of multiple risk factors contemplated by the AIFA’s Nota 79, including: demographic and anthropometric data, femoral and/or lumbar spine BMD T-score, family history of femoral or vertebral fractures, number and site of previous osteoporotic fracture (including vertebral, femoral, and nonvertebral nonfemoral fractures), glucocorticoid treatment (> 3 or > 12 months, ≥5 mg prednisone or equivalent), adjuvant hormone therapy for breast or prostate cancer, and comorbidities that increase the risk (rheumatoid arthritis and other connective tissue diseases, chronic obstructive pulmonary disease, inflammatory bowel diseases, Parkinson’s disease, multiple sclerosis, HIV infection, diabetes, or severe physical handicap).Results:We retrieved data for 10,235 women prescribed with an anti-osteoporotic treatment.Figure 1shows the mean 10-year fracture risk estimated with DeFRAcalc79 tool at the time of the treatment initiation. Teriparatide users had the highest 10-year risk of fracture (67.4% Standard Deviation [SD] 21.5%). We found that in 2,231 patients starting denosumab, the 10-year baseline risk of fracture was 38.5%, SD 22.8%. In 5,759 patients initiating alendronate was 25.7%, SD 15.3% and in patients initiating risedronate was 27.9%, SD 26.9%. Patients prescribed with zoledronic acid had a mean 10-year risk of fracture of 35.6%, SD 21.6. P values between means were all <0.01.Figure 1.Mean 10-year risk of fracture estimated with DeFRAcalc79 tool at the time of treatment initiation, p< 0.01 between all means.Conclusion:The risk of fracture of Italian post-menopausal women initiating different anti-osteoporotic medications varies significantly. Teriparatide is prescribed to patients with greater risk of fracture. The Nota 79 correctly individuates patients at very high risk of fracture that merit treatment with a bone anabolic. Denosumab and zoledronic acid are prescribed to patients with a greater risk of fracture compared to oral bisphosphonates.DeFRAcalc79 is a useful and practical tool for the integrated evaluation of the profile of risk of fracture.References:[1]Kanis JA et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 2019 31:1–12.https://doi.org/10.1007/s00198-019-05176-3[2]Adami G et al. Comments on Kanis et al.: Algorithm for the management of patients at low, high, and very high risk of osteoporotic fractures. Osteoporos Int. 2020. doi: 10.1007/s00198-020-05302-6. [Epub ahead of print]Disclosure of Interests:Giovanni Adami: None declared, Angelo Fassio Speakers bureau: Angelo Fassio reports personal fees from: Abiogen and Novartis, outside the submitted work., Alessandro Giollo: None declared, Giovanni Orsolini: None declared, Ombretta Viapiana: None declared, Davide Gatti Speakers bureau: Davide Gatti reports personal fees from Abiogen, Amgen, Janssen-Cilag, Mundipharma, outside the submitted work., Maurizio Rossini Speakers bureau: AbbVie, Abiogen, Amgen, BMS, Eli-Lilly, Novartis, Pfizer, Sanofi, Sandoz and UCB
48
Talbot, M. "Italian vocal music for chapel and chamber: Masses by Alessandro Scarlatti and Francesco Gasparini: music from the basilica of Santa Maria Maggiore, Rome, ed. Luca della Libera, Recent Researches in the Music of the Baroque Era, cxxxviii (Middleton, WI: A-R Editions, 2004), $80 * Atto Melani, Complete cantatas, ed. Roger Freitas, Yale University Collegium Musicum, Second Series, xv (Middleton, WI: A-R Editions, 2005), $83 * Giovanni Legrenzi, Two cantatas from the Munich manuscript, ed. Barbara Sachs (Richmond: Green Man Press, n.d.), 5.90 * Giovanni Legrenzi, A cantata & two canzonettas for bass and b.c., ed. Cedric Lee (Richmond: Green Man Press, n.d.), 6.90 * Giovanni Legrenzi, Three cantatas for bass and b.c., ed. Cedric Lee (Richmond: Green Man Press, n.d.), 5.90." Early Music 34, no. 4 (2006): 692–94. http://dx.doi.org/10.1093/em/cal096.
Full text
49
Di Paolo, Marilcia. "Francesca De Cesare y Maria Alessandra Giovannini (eds.), Lenguajes de la política. Más allá de las palabras, Nápoles, UniorPress/ Università degli studi di Napoli ‘L’Orientale’, 2019, 296 pp." Olivar 20, no. 32 (2020): e089. http://dx.doi.org/10.24215/18524478e089.
Full text
50
Parrulli, S., M. Cozzi, M. Airaldi, et al. "POS1393 QUANTITATIVE AUTOFLUORESCENCE FINDINGS IN PATIENTS UNDERGOING HYDROXYCHLOROQUINE TREATMENT." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 979.1–979. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2022.
Full textAbstract:
Background:Hydroxychloroquine (HCQ) is a relatively safe and effective drug widely used as primary or adjunctive treatment for several rheumatological and dermatological disorders1. HCQ modulates immune response through several mechanisms and has a tropism for pigmented ocular tissues, particularly retinal pigment epithelium (RPE)2. Its accumulation within RPE cells can lead to sight threatening retinal toxicity, with bull’s eye maculopathy (BEM) representing its advanced phenotype. 3 Quantitative Auto-Fluorescence (qAF) is an imaging modality that allows the measurement of retinal auto-fluorescence following short-wavelength light (488nm) excitation of retinal fluorophores (lipofuscin). 4 Two recent studies have focused on qAF values in patients treated with HCQ 5,6. In both cases qAF was increased in eyes with BEM. Furthermore, Reichel et al.6 were able to detect increased values of qAF in patients without BEM as early as 6 months after the start of HCQ treatment using an experimental imaging analysis procedure.Objectives:To measure quantitative autofluorescence (qAF) in patients under treatment with hydroxychloroquine (HCQ) with no apparent signs of retinal toxicity and to compare it with that of untreated subjects.Methods:Consecutive patients at risk for the development of HCQ retinal toxicity (duration of treatment >5 years or daily HCQ dose >5 mg/kg of actual body weight (ABW) and/or renal insufficiency)7 but no alterations on Spectral Domain - Optical Coherence Tomography, Short-Wavelength Autofluorescence and 10-2 Visual Field examination were recruited. Healthy subject matched by age and sex were also enrolled in the study. All subjects underwent qAF measurements in one eye. Images were analyzed using the conventional qAF grid by Delori calculating the qAF of 8 sectors of the intermediate ring and the mean of those values (qAF8).Results:Thirty-nine patients treated with HCQ (38 females, mean age 52,1 ± 8,6 years) and 39 untreated subjects (38 females, mean age 51,2 ± 8,6 years). In both HCQ patients and untreated subjects, qAF8 was positively correlated with age (p=0.004) (Figure 1). Although HCQ patients showed a higher mean qAF8 compared to untreated subjects (294,7 ±65,3 vs 268,9 ± 57,5), the difference was not significant (p=0.068). HCQ patients showed significantly higher mean qAF values in the inferior-temporal, inferior and inferior-nasal sectors of the intermediate ring of qAF grid compared to untreated subjects (all p<0.05).Figure 1.Visual representation of a model predicting the standardized qAF values as influenced by age and HCQ daily dose/ABW, calculated for a treatment duration of 15 years.Conclusion:These results suggest a possible preclinical increase of qAF values in inferior parafoveal sectors probably induced by HCQ exposure. Further studies are required to improve our understanding of preclinical stages of HCQ retinopathy and the possible role of qAF in the HCQ toxicity screening.References:[1]Haładyj, E., Sikora, M., Felis-Giemza, A. & Olesińska, M. Antimalarials - are they effective and safe in rheumatic diseases? Reumatologia56, 164–173 (2018).[2]Rosenthal, A. R., Kolb, H., Bergsma, D., Huxsoll, D. & Hopkins, J. L. Chloroquine retinopathy in the rhesus monkey. Invest. Ophthalmol. Vis. Sci.17, 1158–1175 (1978).[3]Modi, Y. S. & Singh, R. P. Bull’s-Eye Maculopathy Associated with Hydroxychloroquine. N. Engl. J. Med.380, 1656 (2019).[4]Sparrow, J. R., Duncker, T., Schuerch, K., Paavo, M. & de Carvalho, J. R. L. J. Lessons learned from quantitative fundus autofluorescence. Prog. Retin. Eye Res.74, 100774 (2020).[5]Greenstein, V. C. et al. Quantitative Fundus Autofluorescence in HCQ Retinopathy. Invest. Ophthalmol. Vis. Sci.61, 41 (2020).[6]Reichel, C. et al. Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy. Transl. Vis. Sci. Technol.9, 42 (2020).[7]Yusuf, I. H., Sharma, S., Luqmani, R. & Downes, S. M. Hydroxychloroquine retinopathy. Eye (Lond).31, 828–845 (2017).Disclosure of Interests:Salvatore Parrulli: None declared, Mariano Cozzi Grant/research support from: Bayer, Nidek, Zeiss, Matteo Airaldi: None declared, Francesco Romano: None declared, Francesco Viola: None declared, Piercarlo Sarzi-Puttini: None declared, Giovanni Staurenghi Grant/research support from: Heidelberg Engineering (C), QuantelMedical (C), Centervue (C), Carl Zeiss Meditec (C), Alcon (C), Allergan (C), Bayer (C), Boheringer (C), Genentech (C), GSK (C),Novartis (C), and Roche (C), Optos (F), Optovue (F) and Centervue (F), Alessandro Invernizzi Grant/research support from: Novartis (C), Bayer (C)